AcelRx Pharmaceuticals Inc - ACRX - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

AcelRx Pharmaceuticals Inc - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
ACRX	Nasdaq	2834	http://www.acelrx.com/	9.60 -0.32
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for AcelRx Pharmaceuticals Inc 5 of Last Week's Biggest Winners - Jun 2nd, 2013 6:30 am Nasdaq stocks posting largest percentage increases - May 31st, 2013 4:04 pm 4 Top Small Cap Biotech Acquisition Targets - May 31st, 2013 6:00 am Imprimis' Platform Set To Bring Library Drug Formulations Quickly To Market - May 30th, 2013 6:01 am Wednesday 5/29 Insider Buying Report: ACRX, CSV - May 29th, 2013 11:47 am AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare - May 29th, 2013 5:30 am 5 of Last Week's Biggest Winners - May 26th, 2013 5:15 am This Week in Biotech - May 25th, 2013 5:30 pm 4 Healthcare Stock Stories For Tuesday Investment Wellness - May 21st, 2013 4:43 pm Why AcelRx Pharmaceuticals Shares Spiked Temporarily - May 21st, 2013 12:47 pm AcelRx pain treatment meets late-stage study goals - May 21st, 2013 9:30 am AcelRx pain treatment meets late-stage study goals - May 21st, 2013 9:30 am Home Deport gains on strong results - May 21st, 2013 6:26 am AcelRx announces positive results from Phase 3 study of Sufentanil PCA system - May 21st, 2013 5:36 am Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain - May 21st, 2013 5:30 am AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference - May 16th, 2013 1:20 pm ACELRX PHARMACEUTICALS INC Financials - May 14th, 2013 11:04 am ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex - May 10th, 2013 7:34 am ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an - May 9th, 2013 7:38 am AcelRx Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript - May 8th, 2013 5:38 pm View All Current Headlines >>